The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Oct 12, 2026
Snapshot (as of Oct 12, 2026): Amgen Inc. (AMGN) pays a $9.80 annual dividend ($2.52 quarterly), yielding 2.43% at $414.87/share. Next ex-dividend date 2026-08-21. 13+ consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.43%
Annual Dividend: $9.80 per share
Payout Ratio: 60.9%
Ex-Dividend Date: 2026-08-21
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 16
Amgen Inc. dividend income comes from one of the largest biotechnology companies in the world, built on a portfolio spanning oncology, cardiovascular disease, and inflammatory conditions, with products like Repatha, Enbrel, and Prolia serving patients globally. AMGN currently pays a 2.4% dividend yield. Shareholders receive $9.94 per share annually in quarterly payments, with the next ex-dividend date set for August 21, 2026. A beta of 0.426 means AMGN stock moves far less than the broader market, which suits income investors who prioritize low volatility over maximum yield.
Amgen Inc. pays out 60.4% of earnings as dividends, a payout ratio classified as elevated (60–75%). That level is supported by a broad product lineup serving recurring medical needs, from anemia treatment with Aranesp to osteoporosis prevention with Prolia, categories where patient demand does not disappear with economic cycles. Amgen Inc. dividend safety faces its most visible pressure from that payout ratio sitting near the upper end of the elevated range, leaving less room to absorb earnings disruptions without affecting the dividend.
Amgen Inc. dividend history shows a CAGR of 15.6% per year from 2012 to 2025. The per-share payment grew from $1.44 to $9.52 over that period (2026 data is partial and excluded from this calculation). The smallest annual increase in the window was 5.6% in 2024, a notable step down from the double-digit raises that defined most of the prior decade. Growth is slowing, and that limits how much dividend income AMGN can add on a forward basis compared to its historical pace.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | +7.1% | $7.76 (2022) | $9.52 (2025) |
| 5-Year | +8.3% | $6.40 (2020) | $9.52 (2025) |
| 10-Year | +11.7% | $3.16 (2015) | $9.52 (2025) |
AMGN fits dividend investors who want a biotechnology-sector payer with a long increase streak and below-average market volatility. The yield sits in the moderate (2–4%) range at 2.4%, which is above the stock's own 5-year average of 2.02%, meaning buyers today are getting a better entry yield than the historical norm. The 60.4% payout ratio is the real trade-off: it is high enough to raise questions about headroom, but the company's diversified product base across oncology, nephrology, and cardiovascular medicine provides a broad revenue foundation. Thirteen consecutive years of increases is the defining characteristic here. Income investors get a growing payer with low price volatility; they accept a payout ratio that leaves limited cushion.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-21 | $2.5200 |
| 2026-05-15 | $2.5200 |
| 2026-02-13 | $2.5200 |
| 2025-11-21 | $2.3800 |
| 2025-08-22 | $2.3800 |
| 2025-05-16 | $2.3800 |
| 2025-02-14 | $2.3800 |
| 2024-11-18 | $2.2500 |
| 2024-08-16 | $2.2500 |
| 2024-05-16 | $2.2500 |
| Year | Total Dividends |
|---|---|
| 2026 | $7.5600 |
| 2025 | $9.5200 |
| 2024 | $9.0000 |
| 2023 | $8.5200 |
| 2022 | $7.7600 |
Project income from AMGN with the AMGN dividend calculator or track your full portfolio with the dividend tracker.